Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the ...

NEW YORK-- (BUSINESS WIRE)--Patients with schizophrenia, schizoaffective and schizophreniform disorders who received treatment with intramuscular (IM) administration of aripiprazole (ABILIFY (R)) ...

Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Otsuka and Lundbeck announced results from the first-of-its-kind study comparing the effectiveness of aripiprazole ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...

Dosage for Abilify (aripiprazole) may vary based on the condition it’s being used to treat. Your doctor may adjust your dosing of Abilify over the course of your treatment. The active ingredient in ...

In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery-Asberg Depression Rating Scale ...

Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...